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ABSTRACT
Background and aims: Recently a multidimensional grading
system based on the body mass index (B), degree of airflow
obstruction (O), dyspnea (D) and exercise capacity (E) - the
BODE index - has begun to be used increasingly for the eval-
uation of chronic obstructive pulmonary disease (COPD)
patients. The aim of our study was to investigate the relation-
ship between the BODE index and disease duration, annual
exacerbation and hospitalization rates, health related quality
of life and systemic inflammatory markers like C-reactive
protein (CRP), tumor necrosis factor (TNF)-α and interleukin
(IL)-8.
Materials and methods: In 88 stable COPD patients we evalu-
ated the body-mass index, pulmonary function tests,
Modified Medical Research Council dyspnea scale and six-
minute walk test (6MWT). BODE scores were determined.
Disease duration, number of exacerbations and hospitaliza-
tion in the previous year were recorded. We also performed
arterial blood gases analysis, administered the St. George’s
Respiratory Questionnaire (SGRQ) and measured serum lev-
els of CRP, TNF-α, IL-8. 
Results: According to BODE score 52% of patients were BODE
1, 21% BODE 2, 15% BODE 3 and 12% were BODE 4. There
was a significant relationship between BODE index and COPD
stage as classified according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) (p < 0.001).
Correlations between BODE score and disease duration (p =
0.011), number of exacerbations (p < 0.001) and hospitaliza-
tions (p < 0.001) in the last year were also observed. SGRQ
symptom, activity, emotion scores and total scores were
found to be significantly correlated to BODE (p < 0.001).
Serum CRP levels and BODE were also correlated (p = 0.014);
however, no correlation was found between serum levels of
TNF-α and IL-8 and BODE. 
Conclusions: As the BODE index shows a strong correlation
with various prognostic and follow up parameters of COPD
and systemic inflammation, its use should be considered for
the evaluation of COPD patients.
Keywords: Biomarkers, BODE index, COPD, quality of life.
RIASSUNTO 
Razionale e scopi: Nella valutazione dei pazienti con bronco-
pneumopatia cronica ostruttiva (BPCO) è recentemente in-
valso l’uso in modo crescente di un sistema multidimensiona-
le di misura basato su indice di massa corporea (B), entità
dell’ostruzione funzionale respiratoria (O), dispnea (D) e ca-
pacità di esercizio fisico (E): l’indice BODE. Scopo del nostro
studio era valutare la correlazione tra l’indice BODE e la storia
di malattia, il numero di riacutizzazioni annue e il tasso di
ospedalizzazioni, la qualità della vita legata alla salute e
marker infiammatori sistemici come la proteina C reattiva
(PCR), il fattore di necrosi tumorale (TNF)-α e l’interleuchina
(IL)-8.
Materiali e metodi: Abbiamo valutato in 88 pazienti con BPCO
stabile l’indice di massa corporea, le prove di funzionalità re-
spiratoria, la scala Modified Medical Research Council della di-
spnea ed il test del cammino di 6 minuti (6MWT). Sono stati
calcolati i punteggi BODE. Sono state registrate la durata del-
la malattia, il numero di riacutizzazioni e di ospedalizzazioni
nell’anno precedente. Inoltre sono state effettuate l’emoga-
sanalisi, il St. George’s Respiratory Questionnaire (SGRQ) e
determinati i livelli serici di PCR, TNF-α e IL-8. 
Risultati: Secondo il punteggio BODE 52% dei pazienti erano
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BODE 1, 21% BODE 2, 15% BODE 3 e 12% erano BODE 4. La
correlazione era significativa (p < 0,001) tra indice BODE e
stadio della BPCO determinato secondo la stadiazione del
Global Initiative for Chronic Obstructive Lung Disease
(GOLD). Erano significative anche le correlazioni tra punteg-
gio BODE e durata di malattia (p = 0,011), numero di riacutiz-
zazioni (p < 0,001) e ospedalizzazioni (p < 0,001) nell’ultimo
anno. Il punteggio totale del SGRQ e dei campi sintomi, atti-
vità e emozioni era significativamente correlato al BODE 
(p < 0,001). Anche i livelli serici di PCR e il BODE erano corre-
lati (p = 0,014), mentre non si è rilevata alcuna correlazione
tra TNF-α e IL-8 con il BODE. 
Conclusioni: Dal momento che l’indice BODE mostra una forte
correlazione con vari indici di prognosi, di follow up ed infiam-
matori nella BPCO, una sua applicazione sistematica dovreb-
be essere presa in considerazione nella valutazione dei pa-
zienti con BPCO.
Parole chiave: Biomarker, BPCO, indice BODE, qualità di vita.
INTRODUCTION
Currently, chronic obstructive pulmonary disease
(COPD) is regarded as a systemic disease causing
structural and functional changes in many organs as
well as in the lung. Malnutrition, weight loss, and
peripheral muscle weakness are some of the sys-
temic manifestations of COPD that seriously affect
the health related quality of life and exercise capac-
ity of patients [1,2]. Advances in understanding the
systemic nature of COPD have given rise to the de-
velopment of a combined index of multiple mortal-
ity predictors for this disease known as the “BODE
index”. The components of the index are: body
mass index (BMI), airway obstruction (O), dyspnea
(D) and exercise capacity (E). The BODE index in-
cludes both symptoms and physiological measure-
ments and it has been reported as a better mortality
predictor than forced expiratory volume in 1 sec-
ond (FEV1) [3]. It predicts mortality from any cause
as well as respiratory causes and gives more com-
prehensive information than the FEV1-based staging
system described in the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) [3-5]. 
In view of the systemic nature of COPD, other tools
such as quality of life questionnaires (QoLQ) have
been developed to establish the systemic impacts of
the disease. It has been recommended to administer
QoLQs to determine disease severity and treatment
responses in collaboration with physiological meas-
urements [6]. St. George’s Respiratory Diseases
Questionnaire (SGRQ) was designed specifically for
COPD patients and demonstrates the impact of the
disease on daily life [6,7]. 
Since systemic inflammation has been recognized
as an indisputable component of COPD, the role of
inflammatory cytokines has also been widely inves-
tigated in the natural history of COPD [8]. It has
been shown that C-reactive protein (CRP) levels are
elevated in the serum of COPD patients even in sta-
ble disease [9]. In a follow up study of 8 years, basal
CRP levels significantly predicted overall mortality,
cardiovascular disease-related mortality and can-
cer-related mortality in patients with mild and mod-
erate COPD. FEV1 loss was shown to be correlated
to CRP levels [1] and CRP was found to be a specif-
ic marker of COPD exacerbations [10]. Increased
levels of tumor necrosis factor (TNF)-α have been
found in serum, induced sputum and bronchial
biopsies of COPD patients, especially those in
whom COPD was associated with weight loss [11-
13]. Also, interleukin (IL)-8, a strong selective neu-
trophil chemo-attractant, showed increased levels
in serum of COPD patients with respect to healthy
controls [8].
Currently, clinical outcomes and biomarkers are
two parameters being used to determine the pul-
monary function and systemic effects of COPD. We
think that evaluating COPD, a multicomponent dis-
ease, functionally and systemically will improve
understanding of this disease. In our study we hy-
pothesized that a composite index of clinical out-
comes, the BODE index, was a better predictor of
health status and systemic inflammation in COPD
than FEV1 alone and aimed to investigate the rela-
tionship of the components of BODE and the BODE
index itself with systemic inflammatory biomarkers
and quality of life as well as with prognostic factors
like disease duration and annual exacerbation and
hospitalization rates. 
MATERIALS AND METHODS 
Eighty-eight stable COPD patients diagnosed ac-
cording to GOLD guidelines in our pulmonary dis-
eases outpatient clinic were included in the study
consecutively between November 2006 and May
2007. The study was approved by the human-re-
search Ethical Review board and all patients provid-
ed written informed consent. Inclusion criteria
were: COPD patients in stable conditions (no exac-
erbations due to any reason in the last 6 weeks).
COPD was defined as a history of smoking of more
than 20 pack-years and a FEV1/forced vital capacity
(FVC) ratio of less than 70% after 20 minutes after
salbutamol administration [14]. Exclusion criteria
were: patients with other inflammatory diseases (in-
flammatory bowel disease, rheumatologic diseases,
vasculitis), interstitial lung diseases, active pul-
monary tuberculosis, presence of atopy, history of
myocardial infarction in the last 6 months, decom-
pensated cardiovascular disease and walking dis-
ability.
Demographic features and medical history of the
patients were recorded. Emergency service visits
due to acute exacerbations and hospitalization to
general ward or intensive care unit in the last year
were investigated. Weight, height, dyspnea severity
were measured and the six-minute walking test
(6MWT), pulmonary function tests (PFT) were per-
formed. SGRQ, arterial blood gases (ABG) analysis
and measurement of serum levels of inflammatory
cytokines (CRP, TNF-α, IL-8) were also performed. 
Pulmonary Function Tests: PFT were performed
with the Jaeger Master Screen Pneumo device. The
best test from three consecutive tests was accepted.
FEV1, FVC, FEV1/FVC were measured according to




















 – Indice BO
D



































1 GOLD 2006 [14].
Body Mass Index: BMI was calculated according to
the formula weight (kg) / height (m)2 [15].
Dyspnea Severity: The Modified Medical Research
Council (MMRC) scale was used for the evaluation
of dyspnea [16].
Six-minute walking test: 6MWT was performed in a
35 m long corridor. Patients were motivated to walk
at the fastest speed they could. Oxygen saturation
was measured before and after the test and the dis-
tance walked was recorded [17].
BODE index: The overall index was calculated ac-
cording to BMI, FEV1, 6MWT, MMRC by summing
the points as shown in Table I. Further subgroupings
like BODE 0, 1, 2, 3 were made, as defined in the
formula [3].
Quality of Life Questionnaire: The Turkish transla-
tion of the St. George’s Respiratory Diseases
Questionnaire (SGRQ) was used to determine the
quality of life [18].
Arterial Blood Gases Analysis: ABG samples were
obtained from the radial artery with heparinized in-
jectors and studied with a Roche Diagnostics
GmbH OMNI C, Mannheim (Germany) device with
original reactive analyzers.
Measurement of CRP, TNF-α, IL-8 levels: Venous
blood samples were centrifuged and serums were
separated and preserved at -20° C to be analyzed
together. Serum CRP levels were studied with origi-
nal reactive analyzers (Beckman Coulter Inc. Unicel
DxC 800 Synchron Clinical Systems Galway,
Ireland). Serum TNF-α and IL-8 levels were studied
according to the manufacturer’s recommendations
(BioSource Europe S.A Nivelles, Belgium) with the
Enzyme Linked-Immuno-Sorbent Assay (ELISA)
method.
Intra-assay variation coefficient (%CV) values for 
IL-8 kit were 3.9% for 74.9 pg/ml, 2.6% for 186.2
pg/ml, 5.3% for 991.8 pg/ml while the inter-assay
variation coefficients were 5% for 89.8 pg/ml, 5.5%
for 223.1 pg/ml, 7.8% for 981.2 pg/ml. Lowest
measurement level for IL-8 kit was < 5.0 pg/ml.
Intra-assay variation coefficient values for TNF-α kit
were 5.2% for 8 pg/ml, 4.1% for 167 pg/ml, 3.9%
for 459 pg/ml, while the inter-assay variation coeffi-
cients were 8.5% for 47 pg/ml, 8.2% for 170 pg/ml,
5.9% for 438 pg/ml. Lowest measurement level for
TNF-α kit was 1.7 pg/ml. IL-8 and TNF-α levels
were measured in only 65 of the patients, and CRP
levels in 86 patients according to a table of random
numbers, due to an inadequate number of kits.
Statistical analysis
Data were analyzed by the SPSS 15.0 package pro-
gramme. Spearman’s rank correlations and Pearson
correlations were used to analyze comparisons. 
RESULTS
Demographic characteristics of the 88 patients are
shown in Table II. Duration of the disease ranged
widely, from 6 months to 40 years, in the study pop-
ulation. Sixteen of the patients (18%) were non
smokers but had a history of passive exposure while
72 (82%) were current smokers. Most patients
(53%) had comorbid diseases like hypertension,
congestive heart failure and diabetes mellitus. Fifty-
one (58%) patients had had no exacerbation and 65
(74%) had not been hospitalized in the previous 12
months. Functional parameters and serum cytokine
levels of the study population are shown in Table III.
Of the 88 patients, 16% were stage I, 42% were
stage II, 27% were stage III, and 15% were stage IV
according to GOLD guidelines. When patients
were classified with respect to BODE score, 52%
were BODE 1, 21% were BODE 2, 15% were BODE
3 and 12% were BODE 4. BODE scores and disease
stages of the patients according to GOLD were sig-
nificantly correlated, as expected (p < 0.001)
(Figure 1). 
Each single BODE component and the BODE index
itself were compared with disease duration, number
of exacerbations and number of hospitalizations in
the last year, separately. BMI was not found to be
correlated with any of these parameters. A signifi-
cant relationship was found between MMRC and
disease duration (p = 0.003), number of exacerba-
tions (p = 0.008) and number of hospitalizations 
(p = 0.001). 6MWT was found to be correlated with
disease duration (p = 0.041) and number of hospi-
talizations (p = 0.002). As for FEV1, a significant cor-
relation was observed for disease duration (p = 0.001)
and number of exacerbations (p < 0.001). The
BODE index itself was found to be correlated with
all these parameters, showing the strongest correla-
tion for number of exacerbations and number of
hospitalizations in the last year (p < 0.001 for both).
Among the single components of the BODE index,
BMI was the one that showed the least correlation
(p = 0.020) with BODE (p < 0.001). 
Components of BODE index including BMI, MMRC
dyspnea scale, 6MWT and pulmonary function pa-
rameters (FEV1, FVC and FEV1/FVC) were also com-
pared. There was a significant relationship between
BMI and FEV1/FVC (p = 0.011). MMRC and 6MWT
were also significantly correlated with FEV1 (p <
0.001 for both), FVC (p < 0.001 for both) and
FEV1/FVC (p = 0.016, p = 0.006 respectively). 
All components of BODE index and the BODE in-
dex itself were found to be significantly correlated
with arterial PO2 (p < 0,05). The correlation was de-
termined negative for BODE and PaO2, while it was
positive for BODE and PaCO2 (p < 0.001). 
A significant correlation was observed between
MMRC, 6MWT, FEV1 and SGRQ total score (p <
0.001 respectively). Also, BODE index and SGRQ
symptom, emotion, activity and total scores were
found to be significantly correlated (p < 0.001, re-
spectively) (Figure 2). 
When inflammatory markers were compared with
BODE index, CRP levels were shown to have a
weak but statistically significant correlation (r = 0.2,
p = 0.014) (Figure 3) while TNF-α and IL-8 did not
show a correlation. CRP was not found to be corre-
lated with FEV1, FVC and FEV1/FVC. However, a
significant relationship was found between CRP
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and SGRQ total score (p = 0.015). 
When the patients were divided into two groups ac-
cording to the presence of comorbid diseases, there
was no statistically significant difference with re-
spect to dyspnea severity, 6MWT and CRP levels
between the two groups. 
DISCUSSION
The most recently discussed topic in COPD in the
last few years is its inflammatory and systemic na-
ture. Several clinical tests and biomarkers have
been developed for the evaluation of systemic ef-
fects of the disease [1]. A weak correlation has been
defined between pulmonary function tests, espe-
cially FEV1 and clinical outcomes including the
severity of dyspnea and other symptoms, mortality,
health status, quality of life and frequency of exac-
erbations [18,19]. The BODE index has been sug-
gested as a new follow up tool for the evaluation of
COPD patients [3]. CRP is another systemic bio-
marker that has been widely used for inflammatory
diseases like COPD [8]. 
In our study, among the 88 COPD patients we
found a correlation between BODE index and
COPD stages according to GOLD; this was surely
due to the impact of FEV1 in both GOLD staging
and BODE index. 
Ong et al. found the BODE index and number of
emergency visits related in their study of 16 months
follow up, and also showed a significant but lower
grade relationship between number of emergency
visits and FEV1 [20]. In another study, the BODE in-
dex was shown to be more significant for determin-
ing the severity of COPD exacerbations with re-
spect to FEV1 [21]. In our study, we similarly found
the BODE index to be related to annual rate of hos-
pitalizations (p < 0.001), but this relationship was
not observed for FEV1. However, both BODE and
FEV1 had the same significant relationship for num-
ber of exacerbations (p < 0.001 for both). In the
light of these results, we consider that FEV1 is an im-
portant marker in determining exacerbations within
the other components of BODE, while for hospital-
izations other components of BODE than FEV1 are
more important. 
Weight loss is one of the common systemic effects
of COPD. In a retrospective study of 400 patients
Schols et al. reported increased mortality in severe
COPD patients with chronic hypoxemia and a BMI
< 25 kg/m2 [22]. Another study showed a significant
correlation between fat free mass index (FFMI) and
MRC, FEV1, FEV1/FVC. BMI and FFMI were found to
be related to 6MWT, but there was no correlation
between BMI and disease severity. It was suggested
that FFMI showed a better correlation with disease
TABLE I: SCORING FOR THE COMPONENTS OF THE BODE INDEX: BODY-MASS INDEX, DEGREE OF AIRFLOW OBSTRUCTION,
DYSPNEA, AND EXERCISE CAPACITY  
Points on BODE Index 
Parameter 0 1 2 3
Body mass index (kg/m²) > 21 ≤ 21 - -
FEV1 (% predicted) ≥ 65 50-64 36-49 ≤ 35
6 minute walking distance (m) ≥ 350 250-349 150-249 ≤ 149
MMRC dyspnea scale (score) 0-1 2 3 4
Definition of abbreviation: FEV1, forced expiratory volume in 1st second; MMRC, Modified Medical Research Council.
BODE groups are classified as: 1-2 points: BODE 0; 2-4 points: BODE 1; 4-7 points: BODE 2; 7-10 points: BODE 3.
TABLE II: DEMOGRAPHIC CHARACTERISTICS OF STUDY POPULATION (N = 88) 
Age (mean ± SD) 63.6 ± 10.5
Sex (female/male) 12/76
Disease duration, median (25th to 75th percentile) 5 (2-10) years
Smoking history, median (25th to 75th percentile) 40 (20-60) pack/year
Number of exacerbations, median (25th to 75th percentile) 0 (0-1) /last year
Number of hospitalizations, median (25th to 75th percentile) 0 (0-1) /last year
Comorbid diseases (present/absent) 47/41
Oxygen therapy (present/absent) 8/80
Maintenance therapy with inhaled steroid (present/absent) 49/39






























severity than BMI [23]. In our study, mean BMI of
the patients was 25.7 kg/m2 and a significant posi-
tive correlation was found only with FEV1/FVC. No
correlation was determined between BMI and dis-
ease severity according to GOLD. Also, the rela-
tionship between BMI and BODE index was the
least with respect to the other components. This re-
sult leads us to consider that BMI has little contribu-
tion in determining disease severity. 
Dyspnea, one of the major symptoms of COPD, is a
subjective symptom with perception differences de-
pending on age or individual characteristics. Many
dyspnea measurement scales have been developed
and MMRC is one of the most widely accepted.
Pulmonary function and dyspnea severity have
been reported to be correlated in some studies;
however in other studies dyspnea has been found
uncorrelated with obstruction degree [24-27]. In
our study, MMRC and FEV1, FVC, FEV1/FVC were
found to be related. In addition, a difference of our
study with respect to other studies was the relation-
ship between MMRC and disease duration, annual
exacerbation and hospitalization rates and disease
severity as well as arterial blood gas parameters
(PaO2, PaCO2).
6MWT utilization has recently been increased in
the evaluation of functional status and exercise per-
formance of COPT patients. In our study, similarly
to Marin’s findings [28], 6MWT was found correlat-
ed with MMRC, COPD stage according to GOLD
and PFT parameters. There was also a significant re-
TABLE III: SUMMARY OF FUNCTIONAL PARAMETERS AND SERUM CYTOKINE LEVELS FOR THE STUDY POPULATION  
Number (n) Mean ± SD Minimum Maximum
BMI (kg/m²) 88 25.7 ± 4.9 16.5 37.9
FEV1 (L) 88 1.51 ± 0.6 0.3 2.8
FEV1% predicted 88 53.3 ± 17.4 21 103
FEV1/FVC 88 55.9 ±10.2 28 70
MMRC 88 1.9 ± 1.1 0 4
6MWT (m) 88 375.2 ± 137.0 65 640
BODE index 88 3.1 ± 2.6 0 10
Number (n) Median ± IQR (25th - 75th) Minimum Maximum
SGRQ total score 88 43 (31-62) 7.4 95.8
CRP (pg/ml) 88 0.6 (0.25-1.20) 0.05 14.4
TNF-α (pg/ml) 65 19 (15-21) 12.4 57.7
IL-8 (pg/ml) 65 14 (8-23) 2.5 391.1
Definition of abbreviations: BMI, body mass index; CRP, C-reactive protein; FEV1 (L), forced expiratory volume in 1 second, liter; FVC, forced
vital capacity; MMRC, Modified Medical Research Council; 6MWT, 6-minute walking test; SGRQ, St. George’s Respiratory Disease
























FIGURE 1: RELATIONSHIP BETWEEN BODE INDEX AND COPD
STAGE ACCORDING TO GOLD
Definition of abbreviations: COPD, chronic obstructive pulmonary 






















FIGURE 2: RELATIONSHIP BETWEEN BODE INDEX AND SGRQ
TOTAL SCORES
Definition of abbreviation: SGRQ, St. George’s Respiratory Diseases
Questionnaire.
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lationship between 6MWT and age, disease dura-
tion, and annual hospitalization rates. A distinctive
finding of our study was the correlation between
6MWT and arterial blood gas parameters. In addi-
tion, 6MWT and SGRQ symptom, emotion, activity
and total scores were found to be significantly relat-
ed. In view of these data, 6MWT is suggested as a
first step test for demonstrating the unfavorable ef-
fects of COPD on quality of life and reflecting daily
activities of the patients.
Recent studies have reported that functional param-
eters like FEV1 are insufficient to determine the
health status in COPD, and quality of life measure-
ments have gradually become more important for
COPD [29]. In a study of COPD patients in which
the relationship between BODE index and SGRQ
was investigated, the BODE index was found to in-
crease as SGRQ scores increased. There was a mod-
erate and high relationship between BODE index
and SGRQ; however COPD stage according to
GOLD had a mild correlation with SGRQ [30]. In
another study, a relationship between SGRQ total
score and BODE severity scores was demonstrated;
however this relationship was not observed be-
tween SGRQ total score and disease severity by
GOLD stages [31]. In our study, we also found sig-
nificant correlations between symptom, emotion,
activity and total scores of SGRQ and BODE, and a
weak correlation between all the SGRQ scores and
COPD stage. These results suggest that the BODE
index reflects the effects of disease on quality of life
better than the GOLD stages do.
Several serum biomarkers have been defined in
COPD. Among them, CRP, fibrinogen, interleukins
(IL-6, IL-8), TNF-α and leucocytes are the ones most
studied. Even in stable conditions, all these bio-
markers have been shown to be elevated in COPD
patients [8]. In our study, CRP, IL-8 and TNF-α lev-
els were investigated. In a study by Wu et al., spu-
tum/serum CRP levels and pulmonary function tests
of 30 COPD patients were compared and an in-
verse relationship was observed between
sputum/serum CRP levels and FEV1, and FEV1/FVC
levels [32]. Broekhuizen et al. found lower post
bronchodilator FEV1 levels in patients with high
CRP levels in a group of 102 stable stage II and IV
COPD patients. SGRQ scores were high and exer-
cise capacity evaluated by 6MWT was low in this
group of patients also [33]. Garrod et al. demon-
strated that COPD patients with high CRP levels
had lower quality of life and exercise capacity and
a greater decline in lung functions [34]. In our
study, unlike other studies in similar case series,
CRP and pulmonary function tests were not found
to be correlated. However, SGRQ and CRP were
found to be inversely correlated, while there was a
positive relationship between BODE index, COPD
stage and CRP. 
Nearly half of the patients in our study population
had comorbid diseases like hypertension, conges-
tive heart failure and diabetes mellitus related to
systemic inflammation and this might have inter-
fered with CRP levels, although these comorbidities
had to be under control as an inclusion criterion. In
an observational cohort study, in which moderate to
severe COPD patients and two control groups with-
out COPD (smokers and non-smokers) were tested
using a high sensitivity CRP (hs-CRP) test, CRP lev-
els were found to be elevated in patients with
COPD independent of clinically significant is-
chemic heart disease and cigarette smoking [35].
Emerging laboratory and epidemiologic data have
demonstrated that hs-CRP levels are associated with
impaired insulin sensitivity and the development of
type 2 diabetes [36]. Hence, diabetes mellitus
might not be the cause of the high CRP levels in our
study. However, we analyzed the CRP levels ac-
cording to the presence or not of comorbidities and
no statistically significant difference was observed
between the two groups.
Many studies have shown a relationship between
high TNF-α levels and weight loss in COPD
[37,38]. In our study, we did not find a correlation
between TNF-α levels and body mass index nor
with the BODE index. IL-8 is another important bio-
marker in COPD and some studies have shown
high levels of IL-8 in COPD patients [39], but also
here we were not able to show any correlation be-
tween BODE index and IL-8.
In conclusion, in this study all components of
BODE and the BODE index itself were compared
with most of the clinical outcomes and biomarkers
used in the evaluation of COPD. The most powerful
correlation was observed between 6MWT, MMRC
dyspnea scale and FEV1. The BODE index is a com-
prehensive, feasible and simple clinical scoring sys-
tem in the evaluation of COPD. It also reflects the
quality of life and is correlated with CRP, one of the
biological markers of systemic inflammation, while
there is not a similar relationship with TNF-α and
IL-8. Therefore, BODE is a clinical test which eval-
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FIGURE 3: RELATIONSHIP BETWEEN BODE INDEX AND
SERUM CRP (PG/ML) LEVELS
Definition of abbreviation: CRP, C-reactive protein.





























1 the disease all together. In this study, we showed the
feasibility of BODE and the efficacy of CRP. In the
future, we suggest that BODE could replace FEV1
and could become the standard for the classifica-
tion and clinical evaluation of COPD.
CONFLICT OF INTEREST STATEMENT: None of the authors has
any conflict of interest to declare in relation to the subject
matter of this manuscript. 
  1.  Agusti AG. COPD, a multicomponent disease: implications
for management. Respir Med 2005;99:670-682. 
  2.  Decramer M, De Benedetto F, Del Ponte A, Marinari S.
Systemic effects of COPD. Respir Med 2005;99(Suppl
B):S3-10.
  3.  Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca
M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass
index, airflow obstruction, dyspnea, and exercise capacity
index in chronic obstructive pulmonary disease. N Engl J
Med 2004;350:1005-1012. 
  4.  Celli BR, MacNee W; ATS/ERS Task Force. Standards for the
diagnosis and treatment of patients with COPD: a summary
of the ATS/ERS position paper. Eur Respir J 2004;23:932-
946.
  5.  Global Strategy of Diagnosis, Management and Prevention
of COPD, 2006. www.goldcopd.com. Date accessed:
December 2006. 
  6.  Jones PW. Health status measurement in chronic obstruc-
tive pulmonary disease. Thorax 2001;56:880-887.
  7.  Spencer S, Calverley PM, Sherwood Burge P, Jones PW;
ISOLDE Study Group. Inhaled Steroids in Obstructive Lung
Disease. Health status deterioration in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med
2001;163:122-128.
  8.  Gan WQ, Man SF, Senthilselvan A, Sin DD. Association
between chronic obstructive pulmonary disease and sys-
temic inflammation: a systematic review and a meta-analy-
sis. Thorax 2004;59:574-580.
  9.  de Torres JP, Cordoba-Lanus E, López-Aguilar C, Muros de
Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, Celli
BR, Casanova C. C-reactive protein levels and clinically
important predictive outcomes in stable COPD patients. Eur
Respir J 2006;27:902-907.
10.  Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello
JA, Hagan GW, Vessey RS, Wedzicha JA. Use of plasma bio-
markers at exacerbation of chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2006;174:867-874.
11.  de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers
RM. Elevated TNF-alpha production by peripheral blood
monocytes of weight-losing COPD patients. Am J Respir
Crit Care Med 1996;153:633-637.
12.Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis
factor-alpha levels and weight loss in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med
1994;150:1453-1455.
13.  Mueller R, Chanez P, Campbell AM, Bousquet J, Heusser C,
Bullock GR. Different cytokine patterns in bronchial biop-
sies in asthma and chronic bronchitis. Respir Med
1996;90:79-85. 
14.  American Thoracic Society. Lung function testing: selection
of reference values and interpretative strategies. Am Rev
Respir Dis 1991;144:1202-1218.
15.  Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP.
Prognostic value of nutritional status in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med
1999;160:1856-1861.
16.  Mahler DA, Wells CK. Evaluation of clinical methods for
rating dyspnea. Chest 1988;93:580-586.
17.  ATS Committee on Proficiency Standards for Clinical
Pulmonary Function Laboratories. ATS statement: guide-
lines for the six-minute walk test. Am J Respir Crit Care Med
2002;166:111-117.
18.  Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-
complete measure of health status for chronic airflow limi-
tation. The St George’s Respiratory Questionnaire. Am Rev
Respir Dis 1992;145:1321-1327.
19.  Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The
measurement of dyspnea. Contents, interobserver agree-
ment, and physiologic correlates of two new clinical index-
es. Chest 1984;85:751-758.
20.  Ong KC, Earnest A, Lu SJ. A multidimensional grading sys-
tem (BODE index) as predictor of hospitalization for COPD.
Chest 2005;128:3810-3816.
21.  Marin JM, Sanchez A, Alonso JE, et al. A multivariate grad-
ing system (BODE) as predictor of the severity of exacerba-
tion in COPD (abstract). Am J Respir Crit Care Med
2003;167:A23. 
22.  Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is
a reversible factor in the prognosis of chronic obstructive
pulmonary disease. Am J Respir Crit Care Med
1998;157:1791-1797.
23.  Ischaki E, Papatheodorou G, Gaki E, Papa I, Koulouris N,
Loukides S. Body mass and fat-free mass indices in COPD:
relation with variables expressing disease severity. Chest
2007;132:164-169. 
24.  Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW,
Wedzicha JA. Usefulness of the Medical Research Council
(MRC) dyspnoea scale as a measure of disability in patients
with chronic obstructive pulmonary disease. Thorax
1999;54:581-586.
25.  Fuchs-Climent D, Le Gallais D, Varray A, Desplan J, Cadopi
M, Préfaut CG. Factor analysis of quality of life, dyspnea,
and physiologic variables in patients with chronic obstruc-
tive pulmonary disease before and after rehabilitation. Am J
Phys Med Rehabil 2001;80:113-120.
26.  Sahebjami H, Sathianpitayakul E. Influence of body weight
on the severity of dyspnea in chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2000;161:886-890.
27.  Paula S, Correia D, Morgado R, Fernandes D, Serrador A,
Marques A, Valença J, Almeida A. Correlation between dys-
pnea and lung function evaluated by spirometry and body
plethysmography in COPD patients. Rev Port Pneumol
2005;11(Suppl. 1):22-23.
28.  Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B,
Celli BR. Inspiratory capacity, dynamic hyperinflation,
breathlessness, and exercise performance during the 6-
minute-walk test in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2001;163:1395-1399.
29.  Mahler DA. How should health-related quality of life be
assessed in patients with COPD? Chest 2000;117(2
Suppl):54S-57S.
30.  Ong KC, Lu SJ, Soh CS. Does the multidimensional grading
system (BODE) correspond to differences in health status of
patients with COPD? Int J Chron Obstruct Pulmon Dis
2006;1:91-96.
31.  Medinas Amorós M, Mas-Tous C, Renom-Sotorra F, Rubí-
References





















 – Indice BO
D





Ponseti M, Centeno-Flores M, Gorriz-Dolz M. Health-relat-
ed quality of life is associated with COPD severity: a com-
parison between the GOLD staging and the BODE index.
Chron Respir Dis 2009;6:75-80. 
32.  Wu SJ, Chen P, Jiang XN, Liu ZJ. C-reactive protein level
and the correlation between lung function and CRP levels
in patients with chronic obstructive pulmonary disease.
Zong Nan Da Xue Xue Bao Yi Xue Ban 2005;30:444-446.
33.  Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM.
Raised CRP levels mark metabolic and functional impair-
ment in advanced COPD. Thorax 2006;61:17-22.
34.  Garrod R, Marshall J, Barley E, Fredericks S, Hagan G. The
relationship between inflammatory markers and disability
in chronic obstructive pulmonary disease (COPD). Prim
Care Respir J 2007;16:236-240.
35.  Wouters EF, Creutzberg EC, Schols AM. Systemic effects in
COPD. Chest 2002;121(5 Suppl):127S-130S.
36.  Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M,
Soriano JB, Vessey RS, Celli BR. C-reactive protein in
patients with COPD, control smokers and non-smokers.
Thorax 2006;61:23-28.
37.  Ndumele CE, Pradhan AD, Ridker PM. Interrelationships
between inflammation, C-reactive protein, and insulin
resistance. J Cardiometab Synd 2006;1:190-196.
38.  Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis
factor–alpha levels and weight loss in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med
1994:150:1453-1455.
39.  Kanazawa H, Kurihara N, Otsuka T, Fujii T, Tanaka S, Kudoh S,
Hirata K, Takeda T. Clinical significance of serum concentration
of interleukin 8 in patients with bronchial asthma or chronic
pulmonary emphysema. Respiration 1996; 63: 236-240.
MRM 02-2010_def:Layout 1  08/04/10  15:47  Pagina 91
